iShares Nasdaq Biotechnology Index Fund (IBB) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($2.76 million) and the uptick to downtick ratio was 0.92. The transaction value on upticks was $31.44 million and on downticks, the transaction value was $34.2 million. The transaction value of block trades during downticks was $0.1 million. The money flow was negative ($0 million), indicating the traders were booking profit on the price strength. iShares Nasdaq Biotechnology Index Fund (IBB) rose $0.58 at $284.45, during intraday Tuesday , a rise of 0.2% over the previous days close.
iShares Nasdaq Biotechnology has lost 4.35% in the last five trading days and dropped 3.67% in the last 4 weeks. iShares Nasdaq Biotechnology is up 0.81% in the last 3-month period. Year-to-Date the stock performance stands at -16.17%.
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Funds investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.